I-Mab is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative T-cell engagers and monoclonal antibodies for the treatment of cancer and autoimmune diseases
The company leverages its proprietary technology platform to create therapies that target specific biological pathways, aiming to address unmet medical needs in oncology. With a strong emphasis on research and collaboration, I-Mab works to bring advanced therapies to patients worldwide, enhancing treatment options and outcomes in the field of medicine.
San Diego, CA -- (SBWIRE) -- 10/20/2022 -- An investigation was announced for current long-term investors in shares of I-Mab (NASDAQIMAB) over potential breaches of fiduciary duties by certain directors at I-Mab .
San Diego, CA -- (SBWIRE) -- 09/12/2022 -- An investigation was announced concerning potential securities laws violations by I-Mab in connection with certain financial statements.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab (“I-Mab” or “the Company”) (NASDAQIMAB) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab (“I-Mab” or “the Company”) (NASDAQIMAB) for violations of the securities laws.
